Nitazoxanide Clinical Efficacy, Dosing, and Supportive‑Care Guidelines

FDA‑Approved Indications

Cryptosporidiosis

Off‑Label and Investigational Uses

Rotavirus Enteritis (Viral Gastroenteritis)

Combination Therapy in Allogeneic Stem‑Cell Transplant Recipients

Use in Immunocompromised Populations

Essential Supportive‑Care Measures

Treatment of Diarrheal Infections with Nitazoxanide

FDA-Approved Indications

• The Infectious Diseases Society of America (IDSA) recommends nitazoxanide as a primary indication for treatment of diarrhea caused by Cryptosporidium parvum in immunocompetent children and adults 4
• The Centers for Disease Control and Prevention (CDC) guidelines suggest dosing for children with cryptosporidiosis as follows: Ages 1-3 years: 100 mg orally twice daily, Ages 4-11 years: 200 mg orally twice daily 5, 6
• The CDC recommends dosing for adults with cryptosporidiosis as 500-1000 mg orally twice daily 5
• Clinical response rates for immunocompetent children with cryptosporidiosis are 88% versus 38% with placebo 5, 7
• The IDSA lists tinidazole as first-line treatment for Giardia lamblia infection, with nitazoxanide as an approved alternative 4, 8

Off-Label/Investigational Uses

• Nitazoxanide is an alternative treatment for Cyclospora cayetanensis infection when TMP-SMX cannot be used, although data is limited 4, 6
• Nitazoxanide is a potential second-line alternative for Cystoisospora belli infection when TMP-SMX or pyrimethamine are not suitable 4, 6
• The CDC recommends nitazoxanide for treatment of Enterocytozoon bieneusi (Microsporidiosis) in HIV-infected adults 5, 9

Key Clinical Considerations

• The IDSA recommends using nitazoxanide in immunocompetent patients with confirmed Cryptosporidium or Giardia infection 4
• Nitazoxanide should only be used in HIV-infected patients with cryptosporidiosis in combination with effective antiretroviral therapy (cART) and CD4 >50 cells/µL 4, 6, 7
• The CDC emphasizes the importance of aggressive hydration and electrolyte correction, nutritional supplementation, and cautious use of antimotility agents in young children 5, 7, 10